Table 5.
Down syndrome: Clinical and model metabolic changes (%)*
| substrate | clinical change | CBS × 1.5 H2O2 normal | CBS × 1.5 H2O2 × 2.5 |
| Hcy | -24 | -29 | -35 |
| Met | -47 | -5 | -15 |
| bCys | 15 | 0.2 | 13 |
| bGSH | -14 | 0.2 | -2 |
| SAM | -18 | -21 | -48 |
| SAH | -22 | -26 | -49 |
| Cys | -- | 2 | -55 |
| 5mTHF | -- | 29 | 117 |
| CH2-THF | -- | -14 | -51 |
| 10fTHF | -- | -7 | -34 |
* Clinical data in Column 1 are % changes in blood levels of metabolites averaged over 42 Down patients compared to 38 control patients [13]. Columns 2 and 3 show % changes in model values. In columns 2 and 3, bCys and bGSH indicate model blood concentrations, and the other metabolites are intracellular. Column 2 shows the effect of increasing the dosage of CBS by a factor of 1.5. Column 3 shows the effect of increased CBS combined with moderate oxidative stress. For discussion, see the text.